Anavex Life Sciences Corp (AVXL)

[falconer66a]

More game-changing Anavex science.

New Anavex patent, for analgesia (pain relief):
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210196708%22.PGNR.&OS=DN/20210196708&RS=DN/20210196708

I took the time to read slowly all of Missling’s new patent application. It patents the use of Anavex 1066 (“AV1066") to treat or prevent a diversity of pains.

I was particularly interested to see the evidence for efficacy. Using rather standard and accepted protocols to test for pain relief in lab rats, the new drug was administered in a diversity of dosage regimens for a plethora of pains specifically induced in the rats.

Results were statistically significant (p values of 0.05 or less). Results were not by chance; the induced pains were significantly reduced or eliminated. The stuff works.

I didn’t see any data telling of adverse events, side effects. Those will have to be assessed in human trials.

After some human trials of AV1066 showing both efficacy and safety, a new phrase might emerge: “If it hurts, take AV1066.”

Of course, there is a diversity of existing analgesics. But they are either only moderately effective, or have considerable, even obviating side effects.

Those competent in 8th-grade arithmetic can estimate the revenues this new Anavex analgesic would generate. Nine, ten, or eleven zeros after the integer.

Of course, as before, helpful individuals will caution everyone that mice (and rats) aren’t men; that drugs that test in murines don’t always work in real people. My dollars, however, will stay with my ownership of my AVXL shares. I see Anavex analgesia as another new, giant revenue-generator. Human trials first. Then....